dc.contributor
Institut Català de la Salut
dc.contributor
[González-Callejo P] CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Spain. [García-Astrain C, Herrero-Ruiz A, Henriksen-Lacey M] CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Spain. Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. [Seras-Franzoso J] Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Abasolo I] Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Bioquímica Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
González-Callejo, Patricia
dc.contributor.author
García-Astrain, Clara
dc.contributor.author
Herrero Ruiz, Ada
dc.contributor.author
Henriksen-Lacey, Malou
dc.contributor.author
Seras-Franzoso, Joaquin
dc.contributor.author
Abasolo, Ibane
dc.date.accessioned
2025-10-24T08:56:23Z
dc.date.available
2025-10-24T08:56:23Z
dc.date.issued
2024-06-06T05:47:14Z
dc.date.issued
2024-06-06T05:47:14Z
dc.date.issued
2024-05-29
dc.identifier
González-Callejo P, García-Astrain C, Herrero-Ruiz A, Henriksen-Lacey M, Seras-Franzoso J, Abasolo I, et al. 3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation. ACS Appl Mater Interfaces. 2024 May 29;16(21):27151–63.
dc.identifier
https://hdl.handle.net/11351/11556
dc.identifier
10.1021/acsami.4c04135
dc.identifier
001227980100001
dc.identifier.uri
https://hdl.handle.net/11351/11556
dc.description.abstract
3D bioprinting; Cancer stem cells; Triple-negative breast cancer
dc.description.abstract
Bioimpresión 3D; Células madre cancerosas; Cáncer de mama triple negativo
dc.description.abstract
Bioimpressió 3D; Cèl·lules mare cancerígenes; Càncer de mama triple negatiu
dc.description.abstract
Breast cancer stem cells (CSCs) play a pivotal role in therapy resistance and tumor relapse, emphasizing the need for reliable in vitro models that recapitulate the complexity of the CSC tumor microenvironment to accelerate drug discovery. We present a bioprinted breast CSC tumor-stroma model incorporating triple-negative breast CSCs (TNB-CSCs) and stromal cells (human breast fibroblasts), within a breast-derived decellularized extracellular matrix bioink. Comparison of molecular signatures in this model with different clinical subtypes of bioprinted tumor-stroma models unveils a unique molecular profile for artificial CSC tumor models. We additionally demonstrate that the model can recapitulate the invasive potential of TNB-CSC. Surface-enhanced Raman scattering imaging allowed us to monitor the invasive potential of tumor cells in deep z-axis planes, thereby overcoming the depth-imaging limitations of confocal fluorescence microscopy. As a proof-of-concept application, we conducted high-throughput drug testing analysis to assess the efficacy of CSC-targeted therapy in combination with conventional chemotherapeutic compounds. The results highlight the usefulness of tumor-stroma models as a promising drug-screening platform, providing insights into therapeutic efficacy against CSC populations resistant to conventional therapies.
dc.description.abstract
Funding Sources Financial support was provided by the European Research Council (ERC-AdG-2017 #787510 4DBIOSERS and ERC-2023-POC #101138255 3DTUMOUR). C.G.A. thanks the Spanish State Research Agency for a Juan de la Cierva Incorporación Fellowship (FJCI-2016-28887). I.A. is grateful for the SGR grant from the Catalan Government (2021 SGR 1173). Figures were created using BioRender.
dc.format
application/pdf
dc.publisher
American Chemical Society
dc.relation
ACS Applied Materials & Interfaces;16(21)
dc.relation
https://doi.org/10.1021/acsami.4c04135
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
Mama - Càncer - Tractament
dc.subject
Cèl·lules mare
dc.subject
TECHNOLOGY, INDUSTRY, AND AGRICULTURE::Technology, Industry, and Agriculture::Technology::Printing, Three-Dimensional
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
dc.subject
ANATOMY::Cells::Stem Cells::Neoplastic Stem Cells
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment
dc.subject
TECNOLOGÍA, INDUSTRIA Y AGRICULTURA::tecnología, industria y agricultura::tecnología::impresión tridimensional
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos
dc.subject
ANATOMÍA::células::células madre::células madre neoplásicas
dc.subject
FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.title
3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
